Dr. Zain is on Doximity
As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 E Duarte Road
Duarte, CA 91010Phone(626) 256-4673 x 82405
- Is this information wrong?
Education & Training
NYU School of MedicineFellowship, Hematology, 1996 - 1999- NYU School of MedicineFellowship, Medical Oncology, 1995 - 1997
- NYU School of MedicineFellowship, Hematology, 1994 - 1995
- North Shore University HospitalResidency, Internal Medicine, 1989 - 1992
- Fatima Jinnah Medical CollegeClass of 1987
Certifications & Licensure
CA State Medical License 2002 - 2021
CT State Medical License 2001 - 2003
NY State Medical License 1994 - 2021
NC State Medical License 1992 - 2001- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL) Start of enrollment: 2013 May 01Nikolinakos, P.G.,Foss, F.M.,Beaven, A.W.,Zain, J.,Farber, C.M.,Feldman, T.A.,Cashen, A.,Johnston, P.B.
- A Multicenter, Open-label, Phase 2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2011 May 01Advani, R.,Alberti, S.,Barr, P.,Barrientos, J.C.,Blum, K.,Chang, L.,Choudry, S.,Cummings, J.,Ellstrom, R.,Ford, P.,Fowler, N.,Gerecitano, J.,Gerecitiano, J.,Gonzales, A.,Goy, A.,Habermann, T.,Kenkre, V.,K...
- Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas Brad Haverkos, MD
- Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma Jasmine Zain
- Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma Jasmine Zain
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas Jasmine Zain, MD
Publications & Presentations
PubMed
- The impact of gender, age, race/ethnicity, and stage on quality of life in a spectrum of cutaneous lymphomas.X. Martinez, Arnab Chowdhury, Tracey Stiller, Joycelynne Palmer, Matthew Loscalzo, Estella Barrios, Farah Abdulla, Jasmine Zain, Steven T. Rosen, Christiane Querfeld> ;Supportive Care in Cancer. 2021 May 7
- Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.Stephen M. Ansell, Michael B. Maris, Alexander M. Lesokhin, Robert W. Chen, Ian W. Flinn, Ahmed Sawas, Mark D. Minden, Diego Villa, Mary-Elizabeth M. Percival, Anjali ...> ;Clinical Cancer Research. 2021 Jan 15
- Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.Joo Y. Song, Anamarija M. Perry, Alex F. Herrera, Lu Chen, Pam Skrabek, Michel R. Nasr, Rebecca A. Ottesen, Janet Nikowitz, Victoria Bedell, Joyce Murata-Collins, Yupi...> ;Clinical Cancer Research. 2021 Jan 7
- Join now to see all
Abstracts/Posters
- Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in...Jasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaJasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative AnalysisJasmine Zain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Preliminary Results of the Stapled Peptide ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Two Phase IIa Dose Expansion Cohorts in Relapsed/Refractory TP53 Wild-Type ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 StudiesClinically Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- 6th Annual Conference On How The Experts Treat Hematologic MalignanciesCity of Hope, Santa Monica, California - 9/18/2013
Press Mentions
City of Hope Doctors Present Research on First KRAS Inhibitor and CAR T Cell Therapy at ASCOMay 29th, 2019- City of Hope Clinical and Laboratory Investigators Present New Research at the 60December 4th, 2018
Committees
- Co-Chair, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2017 - Present
- Member, CPRMC (Cancer Protocol Regulatory and Monitoring Committee), City of Hope National Medical Center 2016 - 2017
Professional Memberships
- American Society of HematologyMember
- American Society of OncologyMember
- Member
- American Society for Blood and Marrow TransplantationMember
- International Society of Cutaneous LymphomaMember
- Southwest Oncology GroupMember
Hospital Affiliations
City of Hope's Helford Clinical Research HospitalDuarte, California- City of Hope's Helford Clinical Research HospitalDuarte, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
